Adjuvant portal liver infusion with 5-fluorouracil and mitomycin in colorectal cancer. SAKK.
Between 1981 and 1987, 533 patients from 9 institutions were entered in a randomized trial to assess the value of adjuvant perioperative portal infusion with Fluorouracil and Mitomycin as compared to radical surgery alone. Analysis of 469 evaluable patients at a median follow-up of 5.8 years revealed 110 recurrences in the control and 94 recurrences in the infusion group. Estimated 5-year disease-free survival was 52% and 61% respectively (hazard ratio: 1:0.75; 95% confidence interval 0.57-0.99; p = 0.046). Overall survival was 59% in the control and 69% in the infusion group (p = 0.048). Adjuvant portal infusion did not influence the occurrence of liver metastases but reduced the overall recurrence rate.
Weber
W
W
Clinical Cancer Research Unit, Basel, Switzerland.
Laffer
U
U
Metzger
U
U
D015179:Colorectal Neoplasms / Q000188:drug therapy*; D005472:Fluorouracil / Q000008:administration & dosage*; D006801:Humans; D008937:Mitomycins / Q000008:administration & dosage*; D011168:Portal System; D016019:Survival Analysis
D008937:Mitomycins; D005472:Fluorouracil